Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: A naturalistic case-series outcome study

Journal of Psychopharmacology

Volumn 15, Issue 4, 2001, Pages 297-301

  Dursun, Serdar M ^a,b   Deakin, J F W ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Augmentation; Glutamate; Glutamate hyperfunction; Lamotrigine; Schizophrenia; Topiramate

Indexed keywords

AMPA RECEPTOR ANTAGONIST; CLOZAPINE; FLUPENTIXOL; GLUTAMATE RECEPTOR ANTAGONIST; HALOPERIDOL; KAINIC ACID RECEPTOR ANTAGONIST; LAMOTRIGINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; TOPIRAMATE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0035663840     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988110101500409     Document Type: Article

References (30)

1. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists
2. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited
3. A glutamatergic deficiency model of schizophrenia
4. Clozapine augmentation: Safety and efficacy
5. A two process theory of schizophrenia: Evidence from studies in post-mortem brain
6. Familial and developmental abnormalities of frontal lobe function and chemistry in schizophrenia
7. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia
8. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation
9. Clozapine plus lamotrigine in treatment-resistant schizophrenia
10. D-cycloserine added to clozapine for patients with schizophrenia
11. Double-blind, placebo controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia
12. A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dsyfunction
13. NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia
14. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: Evidence for the glutamate hypothesis
15. Amelioration of negative symptoms in schizophrenia by glycine
16. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
17. Clozapine for the treatment-resistant schizophrenic. A double-blind, comparison with chlorpromazine
18. Preliminary investigations of high-dose oral glycine in serum levels and negative symptoms in schizophrenia: An open label trial
19. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
20. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia
21. Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia
22. An NMDA intervention strategy in schizophrenia with low dose milacemide
23. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics
24. Comparison of glutamate and gamma-aminobutyric acid uptake binding sites in frontal and temporal lobes in schizophrenia
25. Functional anatomy of verbal fluency in people with schizophrenia and those at genetic risk. Focal dysfunction and distributed disconnectivity reappraised
26. The behavioral and neurochemical effects of phencyclidine in humans and animals: Some implications for modeling psychosis
27. Schizophrenia and glutamatergic transmission
28. Glutamatergic aspects of schizophrenia
29. A review of the NMDA receptors and phencyclidine model of schizophrenia
30. Glycine therapy in schizophrenia